Compare Cassava Sciences Inc (FLNA) vs Toyota Motor Corp (TM) Price & Performance

FLNA trades at $0.8168 with minimal daily movement (+0.13%). The stock shows bearish technical signals with negative moving averages but has beaten earnings expectations for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam enables Phase 2a epilepsy trials, providing potential catalyst. However, the company reports zero revenue, negative EBITDA of -$95.19M, and concerning cash flow trends with net cash outflow of -$33.07M in 2025.

While analyst consensus is strongly bullish (67% buy ratings), fundamental weaknesses including negative profitability metrics and cash burn present significant risks. The FDA approval provides near-term optimism for the epilepsy drug pipeline, but execution risk remains high given the company's financial position and lack of current revenue streams.

Toyota Motor trades at $185.30, up 1.31% with bearish technical signals despite strong fundamentals. The stock shows attractive valuation metrics with P/E of 8.38 and P/B of 0.93, while maintaining solid profitability with 8.63% net margin and 12.23% ROE. Recent earnings beats and expanding electrified vehicle sales (37.8% growth in September 2026) support the investment case, though technical indicators suggest near-term pressure.

Toyota presents a value opportunity with strong cash generation and market leadership, but faces headwinds from China sales declines and production disruptions. Analyst consensus leans cautious with 62.5% hold ratings, reflecting concerns about profit margin compression and competitive pressures in key markets.